Spire Wealth Management Purchases 22,192 Shares of Moderna, Inc. (NASDAQ:MRNA)

Spire Wealth Management grew its position in Moderna, Inc. (NASDAQ:MRNA) by 2,150.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,224 shares of the company’s stock after purchasing an additional 22,192 shares during the quarter. Spire Wealth Management’s holdings in Moderna were worth $966,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Tokio Marine Asset Management Co. Ltd. increased its position in Moderna by 15.9% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 12,499 shares of the company’s stock worth $520,000 after acquiring an additional 1,715 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Moderna by 3.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 82,399 shares of the company’s stock valued at $3,426,000 after purchasing an additional 2,788 shares in the last quarter. Everett Harris & Co. CA acquired a new position in Moderna during the 4th quarter worth about $275,000. Caprock Group LLC acquired a new position in Moderna during the 4th quarter worth about $203,000. Finally, EMC Capital Management lifted its position in Moderna by 311.2% during the 4th quarter. EMC Capital Management now owns 1,250 shares of the company’s stock worth $52,000 after buying an additional 946 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 in the last 90 days. Corporate insiders own 15.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on MRNA. JPMorgan Chase & Co. cut their target price on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 26th. Jefferies Financial Group lowered their target price on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research note on Tuesday, October 15th. Barclays lowered their target price on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Leerink Partners decreased their price target on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research note on Thursday, January 16th. Finally, Morgan Stanley decreased their price target on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. Four analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $67.26.

Moderna Stock Down 6.5 %

Shares of NASDAQ MRNA opened at $34.17 on Wednesday. Moderna, Inc. has a 52 week low of $31.94 and a 52 week high of $170.47. The business has a 50-day simple moving average of $40.59 and a two-hundred day simple moving average of $59.22. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The company has a market cap of $13.15 billion, a P/E ratio of -5.87 and a beta of 1.59.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter last year, the company earned ($1.39) EPS. The firm’s revenue was up 3.8% compared to the same quarter last year. Research analysts anticipate that Moderna, Inc. will post -9.18 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.